WSF OpenID Connect Login
Acne affects many women, including young women1-3
Acne is prevalent among women, especially adolescents.1-3 It affects between 50% and 95% of adolescents,1 with many (up to 40%) still affected into their mid-twenties.2
Acne is a known cause of psychological distress, including anxiety and depression4-8
Acne has a significant impact on women’s lives, including anxiety, depression and a reduction in social functioning.4,5
In addition, acne makes women feel less confident, more self-conscious around other people, frustrated and embarrassed,*6 while also impacting their self-esteem.7
The scars left by acne have also been shown to induce further negative psychological effects.8
*A cross-sectional, electronic, web-based observational survey conducted in the US (N=107), acne and breakouts were associated with negative self-perceptions. >75% of participants “agreed” or “strongly agreed” that acne made them feel less confident, more self-conscious around other people, frustrated, and embarrassed.6
- Nast A, Dréno B, Bettoli V et al. J Eur Acad Dermatol Venereol 2012;26(1):1–29. Return to content
- Gollnick HP and Zouboulis CC. Dtsch Arztebl Int 2014; 111(17):301–312. Return to content
- Dawson AL and Dellavalle RP. BMJ 2013;346:f2634. Return to content
- Kellett SC and Gawkrodger DJ. Br J Dermatol 1999;140:273–282. Return to content
- Thomas DR. J Cutan Med Surg 2005;8:3–5. Return to content
- Tanghetti EA, Kawata AK, Daniels SR et al. J Clin Aesthet Dermatol 2014;7(2):22–30. Return to content
- Magin P, Adams J, Heading G et al. Can Fam Physician 2006;52:978–979. Return to content
- Layton AM. Am J Clin Dermatol 2001;2:135–141 Return to content
Yasmin® and YAZ® have beneficial effects on mild-to-moderate acne in women seeking contraception
Yasmin® and YAZ® have antiandrogenic activity without androgenic potential1
- Drospirenone, the progestin in Yasmin® and Yaz®, has a pharmacological profile similar to that of endogenous progesterone1-3
- It combines potent progestogenic activities with antimineralocorticoid and antiandrogenic activities2
- Drospirenone competitively inhibits the binding of androgens to androgen receptors1
- A decrease of ovarian androgen production reduces the severity of acne and seborrhea3
- Muhn P et al. Ann N Y Acad Sci 1995;12;761:311–335. Return to content
- Fuhrmann U, Krattenmacher R, Slater EP et al. Contraception 1996;54(4):243–251. Return to content
- Krattenmacher R. Contraception 2000;62(1):29–38. Return to content
- van Vloten WA, van Haselen C, van Zuuren E et al. Cutis 2002;69:2–15. Return to content
- Boschitsch E, Skarabis H, Wuttke W et al. Eur J Contracept Reprod Health Care 2000;5:34–40. Return to content
- Koltun W, Maloney JM, Marr J et al. Eur J Obstet Gynecol Reprod Biol 2011;155(2):171–175. Return to content
Diane-35 offers effective treatment for women with moderate-to-severe acne caused by androgen excess1-4
In clinical trials, Diane-35® was associated with healing of or clinically significant improvements in acne lesions after 3–6 months of treatment,1-3 with a greater treatment effect with longer duration of treatment.1-4
- In a multicenter clinical trial, Diane-35® was associated with a statistically significant reduction in acne lesions (67%) compared with EE/LNG (27%; P<0.05) after four cycles of treatment.2 After 6 cycles, Diane-35® was associated with a 72% reduction in acne lesions vs 35% with EE/LNG (P<0.0001)2
The therapeutic effect of Diane-35® has not only been observed in facial acne, but to a similar extent in acne lesions on the chest and back.4 Complete clearance of acne on the face, chest and back has been observed in approximately 90% of women after 9 treatment cycles.4
EE/LNG – ethinylestradiol/levonorgestrel
- Aydinlik, S, Lachnit-Fixson U, Lehnert J. Fortschr Med 1986;104:547–50. Return to content
- Carlborg L. Acta Obstet Gynecol Scand Suppl 1986;134:29–32. Return to content
- Erkkola R, et al. Acta Obstet Gynecol Scand 1990;69:61–5. Return to content
- Aydinlik, S, et al. Clinical Trials Journal 1990;27(6):392–402. Return to content